Literature DB >> 8566045

Regulation of Fas(Apo-1/CD95)- and perforin-mediated lytic pathways of primary cytotoxic T lymphocytes by the protooncogene bcl-2.

M Schröter1, B Lowin, C Borner, J Tschopp.   

Abstract

Cytotoxic T cells (CTL) induce cell death of their target cells either by the surface interaction between Fas ligand and Fas or by the release of perforin and granzymes. Both lytic pathways induce apoptosis yet it is not known whether identical or distinct apoptotic pathways are activated. The protooncogene bcl-2 is known to protect various hematopoietic cells from apoptosis induced by diverse agents. Here we show that overexpression of the Bcl-2 protein in the murine mastocytoma line P815 or in concanavalin A-activated splenocytes suppresses apoptotic cell death induced by allospecific primary cytotoxic T lymphocytes (CTL) in which only the Fas lytic pathway was functional. Bcl-2 also reduced target cell killing induced by CTL whose lytic activity was dependent on the perforin/granzyme pathway only. These data provide evidence that, in the target cells studied here, both perforin/granzyme and Fas apoptotic pathways are modulated by Bcl-2 and suggest that these two pathways converge at a step prior to Bcl-2 inhibition.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8566045     DOI: 10.1002/eji.1830251245

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  14 in total

1.  Expression of Bcl-2 in inflammatory sites from patients with active Behçet's disease.

Authors:  K Hamzaoui; A Hamzaoui; L Zakraoui; A Chabbou
Journal:  Mediators Inflamm       Date:  1999       Impact factor: 4.711

2.  Bcl-2 decreases the free Ca2+ concentration within the endoplasmic reticulum.

Authors:  R Foyouzi-Youssefi; S Arnaudeau; C Borner; W L Kelley; J Tschopp; D P Lew; N Demaurex; K H Krause
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

Review 3.  The Fas counterattack: a molecular mechanism of tumor immune privilege.

Authors:  J O'Connell; M W Bennett; G C O'Sullivan; J K Collins; F Shanahan
Journal:  Mol Med       Date:  1997-05       Impact factor: 6.354

4.  Quantification of Bax/Bcl-2 ratios in peripheral blood lymphocytes, monocytes and granulocytes and their relation to susceptibility to anti-Fas (anti-CD95)-induced apoptosis.

Authors:  H J Van Der Vliet; P C Wever; F N Van Diepen; S L Yong; I J Ten Berge
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

5.  Studies of the mechanism of cytolysis by tumour-infiltrating lymphocytes.

Authors:  M Hishii; J T Kurnick; T Ramirez-Montagut; F Pandolfi
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

6.  Detection of Cancer Cell Death Mediated by a Synthetic Granzyme B-like Peptide Fluorescent Conjugate and the same Peptide Binding in Bacteria.

Authors:  Wai Chun Jennifer Lo; Donald Gene Luther
Journal:  J Fluoresc       Date:  2013-10-24       Impact factor: 2.217

7.  Involvement of CD27/CD70 interactions in antigen-specific cytotoxic T-lymphocyte (CTL) activity by perforin-mediated cytotoxicity.

Authors:  S Yamada; K Shinozaki; K Agematsu
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

8.  Apoptosis in acute shigellosis is associated with increased production of Fas/Fas ligand, perforin, caspase-1, and caspase-3 but reduced production of Bcl-2 and interleukin-2.

Authors:  Rubhana Raqib; Caroline Ekberg; Protim Sharkar; Pradip K Bardhan; Arturo Zychlinsky; Philippe J Sansonetti; Jan Andersson
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

9.  Characterization of reaper- and FADD-induced apoptosis in a lepidopteran cell line.

Authors:  D Vucic; S Seshagiri; L K Miller
Journal:  Mol Cell Biol       Date:  1997-02       Impact factor: 4.272

10.  Death-effector filaments: novel cytoplasmic structures that recruit caspases and trigger apoptosis.

Authors:  R M Siegel; D A Martin; L Zheng; S Y Ng; J Bertin; J Cohen; M J Lenardo
Journal:  J Cell Biol       Date:  1998-06-01       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.